# Zenotech Labs (NSE: ZENOTECH) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ZENOTECH · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹270 Cr, it ranks 2111th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was −13.0% in FY10. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹93 Cr (−13.9% year on year) and net profit ₹8 Cr (+343.2%), on a consolidated basis. Promoters held 68.84% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹270 Cr |
| ROE | −13.0% (FY10) |
| ROCE | −11.7% (FY10) |
| Debt to equity | 0.11 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹93 Cr | −13.9% | ₹8 Cr | +343.2% | ₹0.26 |
| Q4 FY26 | ₹177 Cr | +11.4% | ₹45 Cr | +169.2% | ₹1.39 |
| Q3 FY26 | ₹80 Cr | +6.6% | −₹3 Cr | — | −₹0.08 |
| Q2 FY26 | ₹74 Cr | +27.6% | −₹6 Cr | — | −₹0.19 |
| Q1 FY26 | ₹108 Cr | +34.9% | ₹2 Cr | −47.8% | ₹0.06 |
| Q4 FY25 | ₹159 Cr | +36.2% | ₹17 Cr | −90.0% | ₹0.52 |
| Q3 FY25 | ₹75 Cr | +10.3% | −₹4 Cr | — | −₹0.12 |
| Q2 FY25 | ₹58 Cr | −12.4% | −₹4 Cr | — | −₹0.12 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY10 | ₹7 Cr | −₹13 Cr |
| FY09 | ₹6 Cr | −₹18 Cr |
| FY08 | ₹8 Cr | −₹16 Cr |
| FY07 | ₹13 Cr | ₹2 Cr |
| FY06 | ₹12 Cr | −₹4 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 68.84%
- Domestic institutions: 0.01%
- Non-institutions: 30.17%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Ambalal Sarabhai Enterprises](https://app.pivotnow.in/stock/AMBALALSA) | ₹36.20 | ₹277 Cr | 15.6 | — |
| [Espire Hospital](https://app.pivotnow.in/stock/ESPIRE) | — | ₹274 Cr | — | — |
| [Everest Organic](https://app.pivotnow.in/stock/EVERESTO) | — | ₹262 Cr | — | — |
| [Gennex Labs](https://app.pivotnow.in/stock/GENNEX) | — | ₹254 Cr | — | — |
| [Kerala Ayur](https://app.pivotnow.in/stock/KERALAYUR) | — | ₹254 Cr | — | — |
| [Nath Bio-Genes (India)](https://app.pivotnow.in/stock/NATHBIOGEN) | ₹132.60 | ₹252 Cr | 6.3 | — |

## Questions and answers

### What is the market cap of Zenotech Labs?

Zenotech Labs' market capitalisation is ₹270 Cr (₹270 Cr) at the 22 Oct 2026 close, ranking 2111th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Zenotech Labs?

Return on equity was −13.0% in FY10 and return on capital employed was −11.7% in FY10 (consolidated figures).

### Is Zenotech Labs a debt-free company?

No. Zenotech Labs' debt-to-equity ratio was 0.11 in FY10, with total debt of ₹10 Cr.

### What were Zenotech Labs' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Zenotech Labs reported revenue of ₹93 Cr, −13.9% year on year, and net profit of ₹8 Cr, +343.2% year on year.

### What is the shareholding pattern of Zenotech Labs?

As of 30 Jun 2026: promoters 68.84%, domestic institutions 0.01%, non-institutions 30.17%.

### Who are Zenotech Labs' competitors?

The listed Pharma & Healthcare companies closest to Zenotech Labs by market cap are Ambalal Sarabhai Enterprises, Espire Hospital, Everest Organic, Gennex Labs, Kerala Ayur and Nath Bio-Genes (India).

### Is Zenotech Labs a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Zenotech Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ZENOTECH against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.